Compare Amylx Pharmaceuticals Inc (AMLX) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Jones Lang LaSalle Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Jones Lang LaSalle Inc trades at $324.44 (market cap $15.05B). The key difference: Jones Lang LaSalle Inc is far larger — about 7.6× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | JLL | |
|---|---|---|
Market Cap | $1.98B | $15.05B |
Sector | Health | Real Estate |
52-Week High | $18.70 | $358.66 |
52-Week Low | $7.64 | $248.95 |
Enterprise Value | $1.70B | $18.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
JLL trades at $324.44, showing modest daily gains with strong technical momentum and bullish moving averages. The company demonstrates solid fundamental improvement with revenue growth to $26.12B in 2025 and consistent earnings beats. Recent news highlights significant financing deals and Fortune 500 ranking improvement, reflecting strong business execution in commercial real estate services.
JLL presents a compelling investment case with 25% upside to consensus price target of $405.50, supported by improving profitability and positive analyst sentiment. Key risks include commercial real estate market cyclicality and competitive pressures. The stock's current valuation metrics (P/E 17.45, P/S 0.58) appear reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
